Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

CEP-1347

CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase) . As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type p53[1][2][3][4][5][6].

Product Specifications

CAS Number

[156177-65-0]

Product Name Alternative

KT7515

UNSPSC

12352005

Target

JNK; MDM-2/p53; Mixed Lineage Kinase

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cep-1347.html

Purity

98.50

Solubility

10 mM in DMSO

Smiles

C[C@]12N3C4=C(C5=CC(CSCC)=CC=C53)C(CNC6=O)=C6C(C7=C8)=C4N([C@@H](C[C@]2(O)C(OC)=O)O1)C7=CC=C8CSCC

Molecular Formula

C33H33N3O5S2

Molecular Weight

615.76

References & Citations

[1]Saporito MS, Hudkins RL, Maroney AC. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem. 2002;40:23-62. |[2]Mitobe Y, Nakagawa-Saito Y, Togashi K, et al. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells. Anticancer Res. 2022;42 (10) :4727-4733. |[3]Mitobe Y, Suzuki S, Nakagawa-Saito Y, et al. The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo. Biomedicines. 2023;11 (7) :1967.|[4]Maroney AC, Finn JP, Connors TJ, et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 2001;276 (27) :25302-25308. |[5]Maroney AC, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci. 1998;18 (1) :104-111. |[6]Wagner AC, et al. EP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2000;278 (1) :G165-G172.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Isoform

JNK1

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

CDC2 Antibody / CDK1
F44349-0.08ML 0.08 mL

CDC2 Antibody / CDK1

Ask
View Details
C7orf30 (Chromosome 7 Open Reading Frame 30)
244085 50 µL

C7orf30 (Chromosome 7 Open Reading Frame 30)

Ask
View Details
BCAP29 (B-Cell Receptor-Associated Protein 29, BCR-Associated Protein 29, Bap29, BAP29)
406133-01 50 µL

BCAP29 (B-Cell Receptor-Associated Protein 29, BCR-Associated Protein 29, Bap29, BAP29)

Ask
View Details
BCAP29 (B-Cell Receptor-Associated Protein 29, BCR-Associated Protein 29, Bap29, BAP29)
406133-02 100 µL

BCAP29 (B-Cell Receptor-Associated Protein 29, BCR-Associated Protein 29, Bap29, BAP29)

Ask
View Details
Prss16 (NM_001033710) Rat Tagged Lenti ORF Clone
RR214774L3 10 µg

Prss16 (NM_001033710) Rat Tagged Lenti ORF Clone

Ask
View Details
TRPV5 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
48534066 1.0 µg DNA

TRPV5 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

Ask
View Details